Michele Park
InvestorInvestor, Healthcare Team at New Enterprise Associates (NEA) · Board director at Abcuro
About
Michele Park is an investor at New Enterprise Associates focused on the biopharma sector. She previously held investor roles at Clarus Ventures (now Blackstone Life Sciences) and worked as a biotechnology research analyst at Credit Suisse and Piper Jaffray. She holds a PhD in molecular biology from Weill Cornell Graduate School of Medical Sciences, where she completed her dissertation at Memorial Sloan Kettering Cancer Center, and a BA in molecular biology from Princeton.
Invests in
Biotech
Board director at Abcuro
Intro paths
→
In turn, Michele can intro founders to Abcuro's investors below.
Abcuro's investors · 15
abrdn plcEdinburgh · since 2026Bain Capital Life SciencesBoston · since 2026Eurofarma Venturessince 2026Foresite CapitalWest Hollywood · since 2026Mass General Brigham VenturesBostonNew Enterprise Associates (NEA)Menlo Park · $200K – $40M checksNew Leaf Venture PartnersNew York · since 2026Pontifax Venture CapitalHerzeliya · $6.3M – $128M checks · since 2023RA CapitalBoston · since 2026REDMILESan Francisco · since 2026Rock Springs CapitalBaltimore · since 2026Samsara BioCapitalPalo Alto · since 2025Sanofi VenturesCambridge · $5M checks · since 2020ShangBay Capital LLCPalo AltoSoleus CapitalGreenwich · since 2026
Co-founders at Abcuro
SA
Steven A. GreenbergChief Scientific Advisor & Co-Founder
SA
Steven A. Greenberg, MDChief Scientific Advisor & Co-Founder
Colleagues at New Enterprise Associates (NEA)
Aaron Jacobson
Partner at New Enterprise Associates (NEA)
Albert Lee
Advisor at New Enterprise Associates (NEA)
Alex Sharata
Partner at New Enterprise Associates (NEA)
Alexa Grabelle
Associate at New Enterprise Associates (NEA)
Ali Behbahani
Partner, Co-Head of Healthcare at New Enterprise Associates (NEA)
Andrew Schoen
Partner at New Enterprise Associates (NEA)
Ann Bordetsky
Partner at New Enterprise Associates (NEA)
Antony Yang
Investor at New Enterprise Associates (NEA)
Frequently asked questions
- Who is Michele Park?
- Michele Park is an investor at New Enterprise Associates focused on the biopharma sector. She previously held investor roles at Clarus Ventures (now Blackstone Life Sciences) and worked as a biotechnology research analyst at Credit Suisse and Piper Jaffray. She holds a PhD in molecular biology from Weill Cornell Graduate School of Medical Sciences, where she completed her dissertation at Memorial Sloan Kettering Cancer Center, and a BA in molecular biology from Princeton.
- Where does Michele Park work?
- Michele Park is Investor, Healthcare Team at New Enterprise Associates (NEA) and Board director at Abcuro.
- What does Michele Park invest in?
- Michele Park invests in Biotech.